Still Not Enough Data on the Reproductive Safety of Oxcarbazepine (Trileptal)
This meta-analysis is reassuring regarding risk for malformations in children exposed prenatally to oxcarbazepine; however, we still need more data to fully assess reproductive safety.
Weekly Roundup for DECEMBER 30, 2022: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.
Zuranolone: Novel, Rapid-Acting Antidepressant Awaits FDA Approval
A New Drug Application for zuranolone awaits FDA approval for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
Prenatal Exposure to Topiramate (Topamax):Â Impact on Neurodevelopmental Outcomes
Data from a Nordic register-based study observed a significant increase in risk for autism spectrum disorder and intellectual disability in children with prenatal exposure to topiramate.
Best Wishes for the Holiday Season from the MGH Center for Women’s Mental Health
Best wishes for the holiday season from the Center for Women's Mental Health.
Buprenorphine or Methadone: Which One is Better for the Treatment of Opioid Use Disorder in Pregnancy?
Treatment with buprenorphine versus methadone during pregnancy is associated with lower risk of preterm birth, low birth weight, small size for gestational age, and NAS.
Increased Risk of Preterm Birth in Veterans with PTSD
Largest studies to date demonstrate statistically significant risk of preterm birth among women with active PTSD.
Weekly Roundup for DECEMBER 9, 2022: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.